Citrini Bets on Life Sciences After Testing Claude AI Drug Study

Citrini Research, after testing Anthropic's Claude Science, argues that AI-driven drug discovery will accelerate, benefiting life sciences companies. The firm is bullish on the sector's investment opportunities.

• Claude designs protein binders against scorpion neurotoxins; 17 of 211 designs meet criteria2026-10-20
• Claude Science Creates First Complete UV Sky Map2026-10-09
• HHS Plans Sole-Source Anthropic Claude Contract2026-10-21
• Anthropic launches proactive agent Claude Duet2026-10-21
• Anthropic publishes public benefit charter with five pillars2026-10-21